Analyst
Innovative Medicine Leader
Equibles does not estimate personal net worth.
Jennifer Taubert is recorded as Analyst at Innovative Medicine Leader. Johnson & Johnson reported in an 8-K filed August 4, 2026 that Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, effective September 1, 2026. The proxy statement of Johnson & Johnson reports total compensation of $10,225,759 for Jennifer Taubert in fiscal 2021, including a base salary of $938,077. Disclosed compensation is on record for 3 fiscal years. Jennifer Taubert has spoken on 9 earnings calls across 1 company, most recently for Johnson & Johnson on July 15, 2026. The companies whose calls Jennifer Taubert spoke on are classified in the Healthcare sector.
“Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026.”
“For TechValey with sales of $260 million, up 56% versus prior year. And really that was driven by significant launch uptake and share gains across the earlier lines of therapy based on the approval that we got in the U.S. for TechValey plus Darzilex and also continued expansion in the community setting.”
“And just wanted to start with a big thanks to the entire innovative medicine team throughout the world. Really strong results in the first quarter with over $15 billion in net sales, 7.4% operational growth.”
“Yeah, for multiple myeloma, with the data that we saw for Tecveli plus Darzalex in the second-line-plus setting, as well as most recently the Tecveli data in patients who were refractory to anti-CD38 and lenalidomide therapy.”
“So, I'd love to double down on the fact that it really was a great quarter in 3Q, and those numbers that for 90% of our business, we actually grew 16%.”
“You mentioned our achievement of over $15 billion in our first $15 billion quarter. It's important to note that outside of STELARA, which accounts for just 10% of our business, we experienced impressive growth of 15.5%.”
Innovative Medicine Leader
Analyst
Source not stated
Source not stated
Start not stated–2026-09-01
Drug Manufacturers - General · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Johnson & Johnson (JNJ) | EVP, Worldwide Chair Pharmaceuticals | $938,077 | $10,225,759 |
| 2020 | Johnson & Johnson (JNJ) | EVP, Worldwide Chair Pharmaceuticals | $884,615 | $9,532,469 |
| 2019 | Johnson & Johnson (JNJ) | EVP, Worldwide Chair Pharmaceuticals | $796,154 | $7,097,300 |
